Effectiveness of cladribine tablets in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study

被引：0
|
作者：
Habek, M. [1 ]
Brecl, G. Jakob [2 ]
Rajda, C. [3 ]
Adamec, I. [4 ]
Barun, B. [4 ]
Rok, A. [2 ]
Ledinek, A. Horvat [2 ]
Rot, U. [2 ]
Jazbec, S. Sega [2 ]
Gabelic, T. [4 ]
Klivenyi, P. [3 ]
Skoric, M. Krbot [5 ]
机构：
[1] Univ Zagreb, Sch Med, Zagreb, Croatia
[2] Univ Med Ctr Ljubljana, Ljubljana, Slovenia
[3] Univ Szeged, Alber Szent Gyorgyi Hlth Ctr, Szeged, Hungary
[4] Univ Zagreb, Sch Med, Neurol, Zagreb, Croatia
[5] Univ Hosp Ctr Zagreb, Zagreb, Croatia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1135
引用
收藏
页码：894 / 894
页数：1
相关论文
共 50 条
  • [1] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
  • [2] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Michels, Renee Else
    de Fransesco, Maria
    Mahajan, Koshu
    Hengstman, Gerald J. D.
    Schiffers, Krijn M. H.
    Budhia, Sangeeta
    Harty, Gerard
    Krol, Marieke
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (06) : 857 - 873
  • [3] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria de Fransesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    [J]. Applied Health Economics and Health Policy, 2019, 17 : 857 - 873
  • [4] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    [J]. CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [5] Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study
    Brecl Jakob, Gregor
    Barun, Barbara
    Gomezelj, Sarah
    Gabelic, Tereza
    Sega Jazbec, Sasa
    Adamec, Ivan
    Horvat Ledinek, Alenka
    Rot, Uros
    Krbot Skoric, Magdalena
    Habek, Mario
    [J]. NEUROLOGICAL SCIENCES, 2021, 42 (11) : 4591 - 4597
  • [6] Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria De Francesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    [J]. Applied Health Economics and Health Policy, 2020, 18 : 141 - 141
  • [7] Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    [J]. CNS Drugs, 2020, 34 : 447 - 447
  • [8] Alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: Croatian multicenter, observational study
    Habek, M.
    Kes, V. Basic
    Lazibat, I.
    Piskac, S. Kidemet
    Ratkovic, M.
    Komso, M.
    Raspopovic, A. Bogoje
    Barun, B.
    Skoric, M. Krbot
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 671 - 671
  • [9] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    [J]. VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [10] Effectiveness and safety of alemtuzumab in the treatment of active relapsing–remitting multiple sclerosis: a multicenter, observational study
    Gregor Brecl Jakob
    Barbara Barun
    Sarah Gomezelj
    Tereza Gabelić
    Saša Šega Jazbec
    Ivan Adamec
    Alenka Horvat Ledinek
    Uroš Rot
    Magdalena Krbot Skorić
    Mario Habek
    [J]. Neurological Sciences, 2021, 42 : 4591 - 4597
12345